Search Within

Neelam Todi Shah

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Thoracic Oncology (5)
  4. Nursing (2)
  5. Biostatistics Service (1)
  6. Center for Pancreatic Cancer Research (1)

More Groups

People
  1. Vincent Miller (6)
  2. Mark Kris (5)
  3. Antonio Omuro (3)
  4. Lauren Abrey (3)
  5. Barbara Pizzo (2)
  6. Daniel Milton (2)

More People

Years
  1. 2005 (1)
  2. 2004 (3)
  3. 2003 (2)
Publications
  1. Cancer (1)
  2. Clinical Lung Cancer (1)
  3. EJC Supplements (1)
  4. Journal of Clinical Oncology (1)
  5. Lung Cancer (1)
  6. Neuro-Oncology (1)
Publishers
  1. American Society of Clinical Oncology (1)
  2. Elsevier Inc. (1)
  3. Elsevier Ireland Ltd. (1)
  4. Oxford University Press (1)
  5. Pergamon-Elsevier Science Ltd (1)
  6. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
    Journal Article

    Omuro, A. M. P.; Kris, M. G.; Miller, V. A.; Franceschi, E.; Shah, N.; Milton, D. T.; Abrey, L. E.
    Cancer (2005)

    Fulltext@MSK | Save
  • Brain and leptomeningeal metastases in non-small cell lung cancer (NSCLC) responsive to Gefitinib: Is the CNS being left behind?
    Meeting Abstract

    Omuro, A. M. P.; Franceschi, E.; Kris, M. G.; Miller, V. A.; Shah, N.; Abrey, L. E.
    Neuro-Oncology (2004)

    Fulltext@MSK | Save
  • Brain and leptomeningeal metastases in nonsmall cell lung cancer (NSCLC) responsive to Gefitinib
    Meeting Abstract

    Milton, D. T.; Omuro, A. M. P.; Shah, N.; Franceschi, E.; Abrey, L. E.; Miller, V. A.; Kris, M. G.
    Lung Cancer (2004)

    Fulltext@MSK | Save
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Kris, M. G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L. M.; Pao, W.; Rizvi, N.; Pizzo, B.; more...
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial
    Meeting Abstract

    Patel, J.; Miller, V.; Kris, M.; Shah, N.; Tyson, L.; Pizzo, B.; Zakowski, M.; Cespon, M.; Heelan, R.; Johnson, D.
    EJC Supplements (2003)

    Fulltext@MSK | Save
  • Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program
    Journal Article

    Shah, N. T.; Miller, V. A.
    Clinical Lung Cancer (2003)

    Fulltext@MSK | Save